source
- FDA approves Moderna's first mRNA flu vaccine for adults 50 and olderThe Food and Drug Administration has granted approval to Moderna's mRNA flu vaccine, called mFlusiva and previously known as mRNA-1010, making it the first preventive flu shot built on messenger RN…
- Braveheart Bio targets $382 million IPO to fund cardiac drug developmentBraveheart Bio announced an upsized initial public offering on the Nasdaq, aiming to raise about $382.5 million. The company will sell 21.2 million shares at $18 each under the ticker BRVE. The pr…